PSA Test Saves 2 Lives per 1,000 Men Screened

By VirentaNews Staff — May 15, 2026

For every 1,000 men screened for prostate cancer using the prostate-specific antigen (PSA) blood test, just two lives are saved over several years, according to the most extensive analysis of its kind. While this reduction in mortality is statistically significant, researchers emphasize that the absolute benefit is small and must be weighed against the substantial risk of overdiagnosis and overtreatment. Many men diagnosed through screening will undergo invasive procedures—such as biopsies, radiation, or surgery—for cancers that would never have caused symptoms or shortened their lives. The psychological toll, physical side effects like incontinence and erectile dysfunction, and healthcare costs associated with unnecessary interventions complicate the promise of early detection, raising urgent questions about how, and whether, PSA screening should be widely implemented.

The Growing Debate Over Early Detection

Prostate cancer is the second most common cancer in men worldwide, with over 1.4 million new cases diagnosed annually, according to the World Health Organization. The PSA test, introduced widely in the 1990s, measures levels of a protein produced by the prostate gland, with elevated levels potentially signaling cancer. While the test led to a surge in early diagnoses, it also triggered controversy: many detected tumors are slow-growing and unlikely to be lethal. This has led to a longstanding debate in the medical community about balancing the benefits of early detection against the harms of treating indolent disease. The new analysis, which synthesizes data from six major randomized trials—including the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the U.S.-based Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial—provides the clearest picture yet of screening’s real-world impact, confirming that while lives are saved, the trade-offs are considerable.

How the Study Reached Its Conclusions

The comprehensive review, published in The Lancet, analyzed data from nearly 800,000 men across Europe and North America, with follow-up periods extending up to two decades. Researchers focused on the rate of prostate cancer-specific mortality among men who underwent regular PSA testing versus those who received usual care without systematic screening. The pooled results showed a 9% relative reduction in prostate cancer deaths among screened men, translating to two fewer deaths per 1,000 men screened over 10 to 15 years. To prevent one prostate cancer death, 500 men needed to be screened and, critically, 27 additional men would be diagnosed with cancer—many of whom would receive treatments they did not need. The study also found that screening did not significantly reduce overall mortality, suggesting that while prostate cancer deaths declined slightly, other causes of death offset the gains.

Understanding the Risks of Overdiagnosis

The core challenge with PSA screening lies in its inability to distinguish between aggressive, life-threatening cancers and those that are biologically inert. This limitation leads to overdiagnosis—the detection of cancers that would never have caused harm during a man’s lifetime. In the trials reviewed, overdiagnosis rates ranged from 20% to 50%, meaning that for every one to two lives saved, multiple men underwent treatments with significant side effects for cancers that posed no real threat. Active surveillance, where low-risk cancers are monitored rather than immediately treated, has emerged as a strategy to mitigate overtreatment. However, adherence to this approach varies, and many men and physicians still opt for immediate intervention due to anxiety or uncertainty. Experts argue that better risk stratification tools—such as genomic testing and advanced imaging—are needed to refine screening outcomes and ensure that only those at genuine risk receive aggressive therapy.

Who Bears the Burden of Screening?

The implications of PSA screening extend beyond individual patients to healthcare systems and public health policy. Widespread screening programs require significant resources, including lab testing, urological consultations, biopsies, and follow-up care. In countries without universal healthcare, financial barriers may limit access, exacerbating health inequities. Conversely, in systems where screening is readily available, there is a risk of overuse, particularly among older men for whom the harms of treatment may outweigh the benefits. The U.S. Preventive Services Task Force (USPSTF) currently recommends shared decision-making for men aged 55 to 69, acknowledging that the choice to screen should be personalized. For men over 70, the USPSTF advises against routine screening due to limited benefit and increased risk of complications. These guidelines reflect a shift toward precision in preventive medicine, emphasizing informed consent and patient autonomy.

Expert Perspectives

Opinions among oncologists and urologists remain divided. Dr. Andrew Vickers, a biostatistician at Memorial Sloan Kettering Cancer Center, argues that PSA screening has “undeniably reduced prostate cancer mortality” and should be offered with proper counseling. In contrast, Dr. Gil Wolman of the University of Washington warns that “the harms of screening are often underappreciated,” and that focusing on high-risk populations may be more effective than broad screening. Some experts advocate for risk-adapted screening—using family history, genetics, and baseline PSA levels to target testing more precisely—potentially improving the benefit-to-harm ratio.

Going forward, researchers are exploring next-generation biomarkers and artificial intelligence tools to improve the accuracy of prostate cancer detection. Until then, the central challenge remains: how to save lives without sacrificing quality of life. As screening guidelines evolve, the focus will increasingly shift from whether to screen to how to screen smarter.

Source: The Guardian